{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:02:28Z","timestamp":1793779348288,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00125-018-4675-2","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T02:29:38Z","timestamp":1530584978000},"page":"1923-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":354,"title":["Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study"],"prefix":"10.1007","volume":"61","author":[{"given":"Jan W.","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Lundkvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Anders","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Kvarnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Moris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasso","family":"Miliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun-Britt","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Ris\u00e9rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oscarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"4675_CR1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138\u20131153","journal-title":"Gut"},{"key":"4675_CR2","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313:2263\u20132273","journal-title":"JAMA"},{"key":"4675_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","volume":"28","author":"NE Sunny","year":"2017","unstructured":"Sunny NE, Bril F, Cusi K (2017) Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metab 28:250\u2013260","journal-title":"Trends Endocrinol Metab"},{"key":"4675_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","volume":"21","author":"C Koliaki","year":"2015","unstructured":"Koliaki C, Szendroedi J, Kaul K et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21:739\u2013746","journal-title":"Cell Metab"},{"key":"4675_CR5","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461\u20131465","journal-title":"Nat Genet"},{"key":"4675_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2013","unstructured":"Bolinder J, Ljunggren O, Johansson L et al (2013) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:159\u2013169","journal-title":"Diabetes Obes Metab"},{"key":"4675_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13:11\u201326","journal-title":"Nat Rev Nephrol"},{"key":"4675_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ et al (2017) Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation 136:249\u2013259","journal-title":"Circulation"},{"key":"4675_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"4675_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4675_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/hepr.12856","volume":"47","author":"Y Sumida","year":"2017","unstructured":"Sumida Y, Seko Y, Yoneda M, Japan Study Group of NAFLD (2017) Novel antidiabetic medications for nonalcoholic fatty liver disease with type 2 diabetes. Hepatol Res 47:266\u2013280","journal-title":"Hepatol Res"},{"key":"4675_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito D, Shimizu S, Inoue K et al (2017) Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 40:1364\u20131372","journal-title":"Diabetes Care"},{"key":"4675_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2018","unstructured":"Shibuya T, Fushimi N, Kawai M et al (2018) Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes Metab 20:438\u2013442","journal-title":"Diabetes Obes Metab"},{"key":"4675_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jacl.2012.01.002","volume":"6","author":"MH Davidson","year":"2012","unstructured":"Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF (2012) A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova\u00ae compared to Lovaza\u00ae in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol 6:573\u2013584","journal-title":"J Clin Lipidol"},{"key":"4675_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","volume":"56","author":"HM Parker","year":"2012","unstructured":"Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J (2012) Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56:944\u2013951","journal-title":"J Hepatol"},{"key":"4675_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","volume":"147","author":"AJ Sanyal","year":"2014","unstructured":"Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M, EPE-A Study Group (2014) No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterol 147:377\u2013384.e371","journal-title":"Gastroenterol"},{"key":"4675_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","volume":"49","author":"S Dasarathy","year":"2014","unstructured":"Dasarathy S, Dasarathy J, Khiyami A et al (2014) Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 49:137\u2013144","journal-title":"J Clin Gastroenterol"},{"key":"4675_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","volume":"62","author":"CK Argo","year":"2015","unstructured":"Argo CK, Patrie JT, Lackner C et al (2015) Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 62:190\u2013197","journal-title":"J Hepatol"},{"key":"4675_CR19","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","volume":"21","author":"YH Li","year":"2015","unstructured":"Li YH, Yang LH, Sha KH, Liu TG, Zhang LG, Liu XX (2015) Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol 21:7008\u20137013","journal-title":"World J Gastroenterol"},{"key":"4675_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.2337\/dc06-1332","volume":"30","author":"R Caterina De","year":"2007","unstructured":"De Caterina R, Madonna R, Bertolotto A, Schmidt EB (2007) N-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 30:1012\u20131026","journal-title":"Diabetes Care"},{"key":"4675_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.ijo.0800451","volume":"21","author":"C Couet","year":"1997","unstructured":"Couet C, Delarue J, Ritz P, Antoine JM, Lamisse F (1997) Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes 21:637\u2013643","journal-title":"Int J Obes"},{"key":"4675_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/ajcn\/86.5.1670","volume":"86","author":"M Kabir","year":"2007","unstructured":"Kabir M, Skurnik G, Naour N et al (2007) Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 86:1670\u20131679","journal-title":"Am J Clin Nutr"},{"key":"4675_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00125-006-0572-1","volume":"50","author":"M Lundgren","year":"2007","unstructured":"Lundgren M, Svensson M, Lindmark S, Renstrom F, Ruge T, Eriksson JW (2007) Fat cell enlargement is an independent marker of insulin resistance and \u2018hyperleptinaemia\u2019. Diabetologia 50:625\u2013633","journal-title":"Diabetologia"},{"key":"4675_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3945\/ajcn.111.030114","volume":"95","author":"H Bjermo","year":"2012","unstructured":"Bjermo H, Iggman D, Kullberg J et al (2012) Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 95:1003\u20131012","journal-title":"Am J Clin Nutr"},{"key":"4675_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846\u2013854","journal-title":"Hepatology"},{"key":"4675_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1006\/mgme.1997.2658","volume":"63","author":"F Belfiore","year":"1998","unstructured":"Belfiore F, Iannello S, Volpicelli G (1998) Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 63:134\u2013141","journal-title":"Mol Genet Metab"},{"key":"4675_CR27","doi-asserted-by":"publisher","first-page":"29751","DOI":"10.1074\/jbc.M114.565960","volume":"289","author":"S Jiang","year":"2014","unstructured":"Jiang S, Yan C, Fang QC et al (2014) Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem 289:29751\u201329765","journal-title":"J Biol Chem"},{"key":"4675_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/dia.2013.0167","volume":"16","author":"S Mudaliar","year":"2014","unstructured":"Mudaliar S, Henry RR, Boden G et al (2014) Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 16:137\u2013144","journal-title":"Diabetes Technol Ther"},{"key":"4675_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508","journal-title":"J Clin Invest"},{"key":"4675_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/01.mol.0000236363.63840.16","volume":"17","author":"WS Harris","year":"2006","unstructured":"Harris WS, Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17:387\u2013393","journal-title":"Curr Opin Lipidol"},{"key":"4675_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jgh.12656","volume":"30","author":"J Shen","year":"2015","unstructured":"Shen J, Wong GL, Chan HL et al (2015) PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 30:139\u2013146","journal-title":"J Gastroenterol Hepatol"},{"key":"4675_CR32","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","volume":"63","author":"E Scorletti","year":"2015","unstructured":"Scorletti E, West AL, Bhatia L et al (2015) Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol 63:1476\u20131483","journal-title":"J Hepatol"},{"key":"4675_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2008.03.007","volume":"231","author":"P Thulin","year":"2008","unstructured":"Thulin P, Rafter I, Stockling K et al (2008) PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol 231:1\u20139","journal-title":"Toxicol Appl Pharmacol"},{"key":"4675_CR34","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1210\/jc.2013-1250","volume":"98","author":"C Giannini","year":"2013","unstructured":"Giannini C, Feldstein AE, Santoro N et al (2013) Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab 98:2993\u20133000","journal-title":"J Clin Endocrinol Metab"},{"key":"4675_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jhep.2012.10.029","volume":"58","author":"H Li","year":"2013","unstructured":"Li H, Dong K, Fang Q et al (2013) High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 58:557\u2013563","journal-title":"J Hepatol"},{"key":"4675_CR36","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956\u2013965","journal-title":"Lancet"},{"key":"4675_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2337\/db08-1074","volume":"58","author":"A Kotronen","year":"2009","unstructured":"Kotronen A, Seppanen-Laakso T, Westerbacka J et al (2009) Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58:203\u2013208","journal-title":"Diabetes"},{"key":"4675_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/liv.12685","volume":"35","author":"K Yamada","year":"2015","unstructured":"Yamada K, Mizukoshi E, Sunagozaka H et al (2015) Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int 35:582\u2013590","journal-title":"Liver Int"},{"key":"4675_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1749-6632.2002.tb04275.x","volume":"967","author":"B Vessby","year":"2002","unstructured":"Vessby B, Gustafsson IB, Tengblad S, Boberg M, Andersson A (2002) Desaturation and elongation of fatty acids and insulin action. Ann N Y Acad Sci 967:183\u2013195","journal-title":"Ann N Y Acad Sci"},{"key":"4675_CR40","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3945\/jn.108.103754","volume":"139","author":"SH Adams","year":"2009","unstructured":"Adams SH, Hoppel CL, Lok KH et al (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 139:1073\u20131081","journal-title":"J Nutr"},{"key":"4675_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmet.2007.10.013","volume":"7","author":"TR Koves","year":"2008","unstructured":"Koves TR, Ussher JR, Noland RC et al (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45\u201356","journal-title":"Cell Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-018-4675-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:39:04Z","timestamp":1569976744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-018-4675-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["4675"],"URL":"https:\/\/doi.org\/10.1007\/s00125-018-4675-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"27 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LJ is employed by Antaros Medical. MK, TM, G-BF and JO are employed by AstraZeneca. JWE, UR and LL have received consultancy fees for planning of this study. JWE has received research grants or honoraria from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novo Nordisk and Sanofi. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}